Recent Updates
Recently added Catalysts
AIM

AIM ImmunoTech Postpones Investor Conference Call. Will Reschedule for a Later Date

Monday, January 11, 2021 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: OCALA, Fla., Jan. 11, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) and its CEO Thomas K. Equels today announced that this week’s planned investor conference call will be postponed and rescheduled for a later date following the death of Mr. Equels’ mother over

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+20%
120-day peak, hindsight
Typical move
16.5%
average across 4 past catalysts
Cash runway
~6 mo
High dilution risk
Lead asset
poly I-poly C12U
Phase 2 · HIV Seropositivity

Full Press Release Details

OCALA, Fla., Jan. 11, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) and its CEO Thomas K. Equels today announced that this week’s planned investor conference call will be postponed and rescheduled for a later date following the death of Mr. Equels’ mother over this past weekend.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.
Crescendo Communications, LLC
ShareAdd on Google
Tags: AIM Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Jan 11, 2021

Biotech snapshot

Cash runway
$10M liquidity · $2M/mo burn
~6 mo
High dilution risk
Lead asset
poly I-poly C12UPhase 2
HIV Seropositivity →

Catalyst track record

+20%
best trade around AIM's last catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for AIM.

See every catalyst's timing & PoA →